Get started
BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005

BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals Bonds

BIIB fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

BIIB does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company